RCE Financials: Results, Ratios & Statements | Recce Pharmaceuticals

RCE

Recce Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Recce Pharmaceuticals Ltd is an Australian pharmaceutical company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their lead candidate, RECCE® 327, has received Qualified Infectious Disease Product (QIDP) designation from the FDA, offering potential market exclusivity. The company aims to provide effective treatments against a broad range of bacteria and viral indications.

Short position

short percentage0.00%

reported shorts4.3K

shares on issue305.770M

Recce Pharmaceuticals (ASX:RCE) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,267 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.37% in August 2021. RCE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $9.9M (source: ASX (Markit))vs $7.7M (source: ASX (Markit)) (FY25); ASX (Markit), as at 29 Sep 2026
NPAT: −$15.0Mvs −$21.4M (FY25); Yahoo Finance, as at 29 Sep 2026
EPS (diluted): −$0.052vs −$0.090 (FY25); Yahoo Finance, as at 29 Sep 2026

Rev YoY: +29.0%FY
EPS YoY: n/aFY

ASX (Markit)

Summary of Appendix 4E and FY26 Annual Report, 31 Aug 2026

Recce Pharmaceuticals reported a net loss of $14.96 million for the year ended 30 June 2026, a 30% improvement from the prior year's loss of $21.43 million, driven by lower R&D expenditure. No dividend was declared. The company is advancing its anti-infective pipeline, with patient dosing underway in a registrational Phase 3 trial for Diabetic Foot Infections and positive preclinical data for its lead candidate R327.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: −233.0%
Net margin: −150.5%
FCF margin: −100.1%
ROE: n/a
ROA: −142.9%
FCF conversion: n/a
Net debt (excl. leases): $7.1M
Net debt / EBITDA: n/a
Current ratio: 0.4×
Interest cover: −14.5×
Cash dividends paid / net profit: n/a
Market cap: $85.3M
P/E: n/a
P/B: n/a

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

RCE income, newest period first, figures in AUD
Line item	FY26	FY25	FY24	FY23
Revenue	$9.9M (source: ASX (Markit))	$7.7M (source: ASX (Markit))	$5.2M (source: ASX (Markit))	$4.4M (source: ASX (Markit))
Operating income	−$23.2M	−$28.0M	−$22.1M	−$17.2M
EBITDA	−$13.0M	−$19.9M	−$16.5M	−$12.7M
EBIT	−$13.4M	−$20.3M	−$16.9M	−$12.9M
Interest expense	$1.6M	$1.2M	$806.6K	$172.6K
Pretax income	−$15.0M	−$21.4M	−$17.7M	−$13.1M
Tax	$0	$0	$0	$0
NPAT	−$15.0M	−$21.4M	−$17.7M	−$13.1M
Net interest income	−$1.6M	−$1.2M	−$659.8K	−$117.1K
EPS basic	−$0.052	−$0.090	−$0.099	−$0.074
EPS diluted	−$0.052	−$0.090	−$0.099	−$0.074
Shares	289.2M	288.4M	205.9M	181.8M

ASX (Markit)

Financial reports

The company's own filings, newest first

Showing 10 of 27 reports